BPC-157

BPC-157 is described as a stable pentadecapeptide investigated across injury and inflammation models for systemic recovery and inflammation research.

$120.00

Collections

Review Third-Party Certificates of Analysis:

COA

Core Analytical Specifications:

Chemical Purity Assay

Net Mass Verification

Microbial Sterility Screening

Endotoxin (LPS) Detection

Verified
Purity
Thresholds

Independent
COA
Validation

Secure
Trackable
Shipping

Synthesized, Analytically Verified, and Dispatched from United States.

Molecular Design & Functional Mechanism

BPC-157 is described in the literature as a stable Penta decapeptide investigated across injury and inflammation models, commonly framed around cytoprotective signaling and nitric-oxide–related pathways. 

What Research Shows 

  • Preclinical breadth: Publications describe broad effects across GI and wound models, often highlighting pleiotropic outcomes in animal systems. 
  • Clinical-trial references (historical): Some papers state it has been reported safe in clinical trials for inflammatory bowel disease under an identifier (PL14736). 

Why Research Teams Choose Us

  • Systems peptide: when researchers want multi-pathway repair hypotheses rather than single-target pharmacology.
  • High preclinical signal density allows screening across tissues and endpoints (with evidence strength varying by indication).
Molecular Design & Functional Mechanism

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Tirzepatide is engineered to activate GIPR + GLP-1R simultaneously, enabling coordinated incretin signaling for appetite regulation, glycemic physiology, and energy-balance research. The clinical program positions it as a high-ceiling comparator for next-gen incretin work.

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. Foundation Plus supplies compounds intended for laboratory research and development purposes. Products are not promoted for consumer, medical, or veterinary use. These products are not drugs, food additives, or dietary supplements and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.

Related Products

Leave a review

Compliance & Age Verification

Access to the Foundation Plus digital storefront is strictly restricted to individuals 21 years of age or older.

The compounds available on this site are intended solely for laboratory research purposes. These materials are not designed to prevent, treat, or cure any medical condition and are strictly not for human consumption. By entering this site, you verify that you meet the age requirement, acknowledge these clinical restrictions, and possess a legitimate research basis for the procurement of these products.

Please note that all compounds are provided as individual units.

I am under 21 / Exit